Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kristoffer K. Vinding"'
Autor:
Dorte Marker, Katrine Carlsen, Pia Munkholm, Henriette Elsberg, Johan Burisch, Tine Thorkilgaard, Margarita Elkjaer, Erika Belard, Kristoffer K. Vinding, Natalia Pedersen
Publikováno v:
Inflammatory bowel diseases. 22(2)
Background Fecal calprotectin is a reliable noninvasive marker for intestinal inflammation usable for monitoring patients with inflammatory bowel disease. Tests are usually performed by enzyme-linked immunosorbent assay (ELISA), which is time consumi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::646209372fcbdda4ade225a8c9dd0987
https://pubmed.ncbi.nlm.nih.gov/26535869
https://pubmed.ncbi.nlm.nih.gov/26535869
Autor:
Johan Burisch, Tine Thorkilgaard, Dorte Marker, Henriette Elsberg, Pia Munkholm, Katrine Carlsen, Natalia Pedersen, Kristoffer K. Vinding
Publikováno v:
Gastroenterology. 148:S-193
significantly younger, had shorter disease duration and underwent a greater number of CD related surgeries during the study period (Table 1). For the entire study cohort, LS1 ranged from 0-54 (mean 8.76±6), LS2 ranged from 0-46 (mean 9.98±8) and DL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a2f3e96b7b177214f2a5b96d94bfb9a6
https://doi.org/10.1016/s0016-5085(15)30641-7
https://doi.org/10.1016/s0016-5085(15)30641-7
Autor:
Selwyn Odes, Johan Burisch, John Kaimakliotis, K R Nielsen, Natalia Pedersen, Peter L. Lakatos, Dana Duricova, Konstantinos Katsanos, Zsuzsanna Vegh, Pia Munkholm, Kristoffer K. Vinding
Publikováno v:
Gastroenterology. 148:S-468
Background: The ECCO-EpiCom study investigates the differences in the incidence, disease characteristics and therapeutical management of inflammatory bowel diseases (IBD) between Eastern and Western Europe. The aim of this study was to analyze the di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73f10d324a9666e941a5d41da396f64b
https://doi.org/10.1016/s0016-5085(15)31576-6
https://doi.org/10.1016/s0016-5085(15)31576-6
Autor:
Natalia Pedersen, Katrine Carlsen, Zsuzsanna Vegh, Andreas Petersen, Christina Casen, Johan Burisch, Pia Munkholm, Dorit Vedel Ankersen, Kristoffer K. Vinding
Publikováno v:
Gastroenterology. 146:S-241
Background: Glucocorticoids (GCs) are steroid hormones used to induce remission in moderate-to-severe inflammatory bowel disease (IBD). A substantial fraction of patients do not respond to GC treatment and require alternate therapies or surgery. At p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3cfa693ccf17655785abeda5960d8683
https://doi.org/10.1016/s0016-5085(14)60849-0
https://doi.org/10.1016/s0016-5085(14)60849-0